The ABCD nationwide IDegLira audit is an independent audit supported by an unrestricted grant from Novo Nordisk Ltd

ABCD nationwide IDegLira audit – first visit data collection form



| Clinician | | | | | Centre | | | | | | | |
|---|--|--------------------------|--------------|---|---------------------------|--|---|---------------|------------|----------------|--|--|
| Patient Identifica | ntion | | | | | | | | | | | |
| Please record | – AFFIX PATIENT LA OR patient name, gend | | f birth belo | — — ¬ | White | ☐ British☐ Irish☐ Any Ot | her White Background | | | | | |
| Patient name | | | | | Mixed | ☐ White a | and Black Caribbean and Black African and Asian her Mixed Background | | | | | |
| Gender | Male Female (circle one) | | | | Asian or Asian British | ☐ Indian ☐ Pakista ☐ Bangla | ni | | | | | |
| Date of birth | / / (dd/mm/yyyy) | | | | Black or Black British | ☐ Caribbe | ☐ Any Other Asian Background ☐ Caribbean ☐ African ☐ Apy Other Plack Background | | | | | |
| Date of visit | / / _(dd/mm/yyyy) Age | | | | Other Ethnic Groups | ☐ Any Other Black Background ☐ Chinese ☐ Any Other Ethnic Group ☐ Not stated | | | | | | |
| First Visit - Baseli | ne Medical Histor | v | | | | | | | | | | |
| Duration of diabetes | | | | years | | | | | | | | |
| Type of diabetes | Type 1 | Type 2 | Othe | r (ci | rcle one) If other p | olease specif | y: | | | | | |
| HbA _{1c} | pl | lease enter eithe | r | % | · · · · · · | or | mmol/mol D | ate of test | | $\overline{1}$ | | |
| Date of blood test | | | | | | | | , | | | | |
| Blood pressure SBP | mmHg | | | | Blood pressure DI | ВР | mmHg D | ate of test | | | | |
| Triglyceride [| mmol/L | Date of tes | st | | Н | DL | mmol/L D | ate of test [| | | | |
| Total cholesterol | mmol/L | Date of tes | it | | Serum creatinii | ne | μmol/L Date of test | | | | | |
| Height | m | m | | | Current weig | ht | kg D | Date of test | | | | |
| BMI will be auto-calcula | ted when data is entere | d into online au | dit form | Alanine | e aminotransferase A | LT | IU/L D | ate of test | | | | |
| Pancreatitis and Bar Has the patient ever pancreatitis? | | No (circle | one) | Has the p | atient ever had B | ariatric Surg | gery? | Yes | No | (circle one) | | |
| Details | | | | | | | | | | | | |
| Rationale for startin | g IDegLira? | | | | | | | | | | | |
| Problems with hypo | Voc | No (circle | one) | Poor com | pliance, e.g. need | l flexible inje | ection timing | Yes | No | (circle one) | | |
| Need more than 80 IU/day Yes No (circle one) | | | | Highly variable glucose values with current insulin regime Yes No | | | | | | (circle one) | | |
| Achieving glycaemic control Yes No (circle one) | | | | To fit in with variably timed visit by third party to administer (e.g. district nurse, relative) Yes No (c | | | | | | (circle one) | | |
| Stop or reduce weight gain Yes No (circle one) | | | one) | Preferred once-daily combination regimen Voc. No. | | | | | | (circle one) | | |
| If other please speci | fy | | | | | | | | | | | |
| Patient Satisfaction Place 'x' on Visual Ar Patient option of antidia | | | | | | | □ 0 □ 1 □ | 2 🗆 3 | 4 □ | 5 🗆 6 | | |
| Any other patient co | omments? | | | Any othe | r doctor/nurse co | mments? | | | | | | |
| First visit - Curre | nt Medications be | fore initiation | on of IDeg | Lira | | | | | | | | |
| Please circle the drugs that t | he patient is on | | | | | | | | Total | Dose | | |
| Biguanides Drug name Metformin Enter total dose including that | | | | | combination tablets | | | | | mg/day | | |
| Sulphonylureas | Drug name Chlo | prpropamide | benclamide | Gliclazide | Gliclazide MR | Gliclazide SR | Glimepiride | Glipizide | | mg/day | | |

| | | | | | | | | | | Total | Dose |
|--|---|--|---|--------------------------------------|--------------------------------------|--|--|--|------------|----------|--------------------------------|
| TZDs & TZDs with metformin | Drug name | Pioglitazone | Pioglitazone + r | metformin | Rosiglitazone | Rosiglitazone + | metformin | nter only dose o | of TZD | | mg/day |
| Meglitinides | Drug name | Nateglinide | Repaglinide | | | | | | | | mg/day |
| Alpha-glucosidase inhibitors | sidase inhibitors Drug name Acarbose Acarbose | | | | | | | | | | mg/day |
| GLP-1 agonist | Drug name | Exenatide Liraglutide Exenatide (once-weekly) Exenatide qw Lixisenatide Dulaglutide | | | | | | | | | mg/day |
| SGLT2 inhibitors | Drug name | Dapagliflozin Canagliflozin Empagliflozin | | | | | | | | | |
| DPP-4 inhibitors and DPP-4 inhibitors with metformin | | | | | | | | | | | |
| | | Saxagliptin | Saxagliptin + n | netformin | Sitagliptin | Sitagliptin + m | etformin | | | | |
| | | Vildagliptin | lagliptin Vildagliptin + metformin Enter only dose of DDP-4 inhibitor | | | | | | | | mg/day |
| Insulin – rapid/short acting | Drug name | Actrapid | Apidra | Fiasp | Humalog | Humalog | S Insumar | n Rapid | | | units/day |
| | | NovoRapid | Other | | | | | | | | |
| Insulin – long/ intermediate acting | Drug name | Abasaglar | Humulin I | Insulatard | Insuman Ba | sal Lantus | Leve | mir | | | units/day |
| | | Tresiba | Other | | | | | | | | |
| Insulin – biphasic | Drug name | Humalog Mix 25 Humalog Mix 50 Humulin M3 Insuman Comb 15 Insuman Comb 25 Insuman Comb 50 | | | | | nb 50 | | units/day | | |
| | | NovoMix 30 | Other | | | | | | | | |
| Other antidiabetic medications of which could affect glycaemic co | | ons Drug na | ime | | | | | | | | mg/day |
| Anti-obesity medication Drug name Orlistat Sibutramine | | | | | | | | | | mg/day | |
| First Visit - Hypoglyca | emia His | tory | | | | | | | | | |
| First Visit - Hypoglycaemia History Please give best estimate. For example, if over the last 3 months a patient has had on average 2 mild hypos per week, then enter 24 as your best estimate of the number over the last 3 months. | | | | | | | | | | | r in last onths |
| Minor Self-treated (symptoms/al | ucose vali | ies not require | -d) | | | | | | | | |
| Severe | 3rd party intervention (defined as patient could not have self-treated. Excludes cases where a patient could have | | | | | | | | | | |
| Nocturnal | | | | | | | | | | | |
| Either minor or severe, 00 | | ed) | not have self-t | reated. Exc | ludes cases w | vhere a patier | nt could ha | ve | | | |
| | | ed) | not have self-t | reated. Exc | ludes cases w | vhere a patier | nt could ha | ve | | | |
| Initiation of IDegLira Start dose | | ed) | | reated. Exc | ludes cases w | vhere a patier | nt could ha | ve | | | |
| Initiation of IDegLira | :00 to 06:0 | ed) 00 | os | reated. Exc | | | | ve please spec | cify: | | |
| Initiation of IDegLira Start dose | :00 to 06:0 | dose step | os | her Pati | ent Relat | | If other | | | | |
| Initiation of IDegLira Start dose Who will administer IDeg Proposed time of IDegLira | :00 to 06:0 | dose step | os ssional Ot Evening/bedt | her Pati | ent Relat htime Moi | ive (circle one) | If other | please spec If variable please spec | | No | (circle one) |
| Initiation of IDegLira Start dose Who will administer IDeg Proposed time of IDegLira administration: | :00 to 06:0 | dose step | os ssional Ot Evening/bedt | her Pati | ent Relat htime Moi | ive (circle one) | If other | please spec If variable please spec | cify: | No | (circle one) |
| Initiation of IDegLira Start dose Who will administer IDeg Proposed time of IDegLira administration: | :00 to 06:0 | dose step | os ssional Ot Evening/bedt | her Pati | ent Relat htime Moi | ive (circle one) | If other | please spec If variable please spec | Yes | No | |
| Initiation of IDegLira Start dose Who will administer IDeg Proposed time of IDegLira administration: | :00 to 06:0 | dose step Health profe Afternoon | os ssional Ot Evening/bedt | her Pati | ent Relat htime Moi | ive (circle one) rning Variak other antidia | If other | please spec If variable please spec | cify: | No Added | (circle one) Stopped/ Switched |
| Initiation of IDegLira Start dose Who will administer IDeg Proposed time of IDegLira administration: Date of initiation of deglu | :00 to 06:0 | dose step Health profe Afternoon | os ssional Ot Evening/bedt | her Pati ime Lunc (dd/mm/yyyy) | ent Relati htime Moi Change in | ive (circle one) rning Variat other antidia | If other Ole (circle one) betic media | please spec If variable please spec cation? | Yes Change | | Stopped/ |
| Initiation of IDegLira Start dose Who will administer IDeg Proposed time of IDegLira administration: Date of initiation of deglu | Lira? [udec: [| dose step Health profe Afternoon | os ssional Ot Evening/bedt / | her Pati ime Lunc (dd/mm/yyyy) | ent Relati htime Moi Change in | ive (circle one) rning Variate other antidia | If other Ole (circle one) betic media | please spec If variable please spec cation? | Yes Change | | Stopped/ |

| | | | | | | | New Dose | No Change | Change Dose | Added | Stopped/ Switched |
|--|-----------|--|-------------------------------------|-----------------|--------------------|--|-----------|-----------|----------------|-------|----------------------|
| TZDs & TZDs with metformin | Drug name | Pioglitazone P | Pioglitazone + me | etformin | | | | | | | |
| | | Rosiglitazone | Rosiglitazone + m | etformin Enter | only dose of TZD | | mg/day | | | | |
| Meglitinides | Drug name | Nateglinide F | Repaglinide | | | | mg/day | | | | |
| Alpha-glucosidase inhibitors | Drug name | Acarbose | | | | | mg/day | | | | |
| GLP-1 agonist | Drug name | Exenatide | Liraglutide | Exenatide (once | e-weekly) | | | | | | |
| | | Exenatide qw L | Lixisenatide | Dulaglutide | | | mg/day | | | | |
| SGLT2 inhibitors | Drug name | Dapagliflozin | Canagliflozin | Empagliflozin | | | mg/day | | | | |
| DPP-4 inhibitors and DPP-4 inhibitors with metformin | | | | | | | | | | | |
| | | Linagliptin + metformin Sitagliptin + metformin | | | | | | | | | |
| | | Sitagliptin | Sitagliptin Saxagliptin + metformin | | | | | | | | |
| | | Vildagliptin Wildagliptin + metformin Enter only dose of DDP-4 inhibitor | | | | | mg/day | | | | |
| Insulin – rapid/short acting | Drug name | Actrapid | Apidra | Fiasp | Humalog | | | | | | |
| | | Humalog S Ins | suman Rapid | NovoRapid | Other | | units/day | | | | |
| Insulin – long/ intermediate acting | Drug name | Abasaglar | Humulin I | Insulatard | Insuman Basal | | | | | | |
| | | Lantus | Levemir | Tresiba | Other | | units/day | | | | |
| Insulin – biphasic | Drug name | Humalog Mix 25 | umalog Mix 50 | Humulin M3 | Insuman Comb 15 | | | | | | |
| | | Insuman Comb 25 | Insuman Comb 50 | NovoMix 30 | Other | | units/day | | | | |
| Other antidiabetic medications or medications which could affect glycaemic control | Drug name | | | | | | mg/day | | | | |
| Anti-obesity medication | Drug name | Orlistat S | Sibutramine | | | | mg/day | | | | |